| Name | 1-[[1-[4-[(dimethylamino)methyl]phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea |
|---|---|
| Synonyms |
1-[[1-[4-(dimethylaminomethyl)phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea
Urea,N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl] |
| Description | Nevanimibe (PD-132301; ATR101) is a selective and potent acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe (PD-132301; ATR101) inhibits ACAT2 with an EC50 of 368 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
ACAT1:9 nM (EC50) ACAT2:368 nM (EC50) |
| In Vitro | Coincubation of Nevanimibe (ATR-101; 3 nM-30 μM) and Cholesterol markedly increases toxicity in a dose-dependent manner, where 3 nM Nevanimibe in the presence of 60 μg/mL Cholesterol reduces survival by 60% after 24 hours. All doses of Nevanimibe (3 nM-30 μM) induces cytoxicity in the presence of Cholesterol, whereas treatment with Cholesterol in the absence of Nevanimibe has no effect on cell viability[1]. Cell Cytotoxicity Assay[1] Cell Line: The H295R and HAC clone 15 (HAC15) human ACC cell lines Concentration: 3 nM-30 μM Incubation Time: 24 hours Result: 3 nM-3 μM exhibited no toxicity, whereas 30 μM treatment reduced survival by approximately 40% within 24 hours. |
| References |
| Density | 1.062g/cm3 |
|---|---|
| Boiling Point | 528.1ºC at 760mmHg |
| Molecular Formula | C28H41N3O |
| Molecular Weight | 435.64500 |
| Flash Point | 273.2ºC |
| Exact Mass | 435.32500 |
| PSA | 47.86000 |
| LogP | 6.90590 |
| Vapour Pressure | 3.05E-11mmHg at 25°C |
| Index of Refraction | 1.58 |
| Storage condition | 2-8℃ |